1887

Abstract

Helicobacter pylori infection is associated with chronic gastritis, peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma. The limitations of current therapies for H. pylori infection include poor compliance and antibiotic resistance. Therefore, an effective anti-H. pylori vaccine would be an alternative or complement to antibiotic treatment. Urease B (UreB) is considered an ideal vaccine antigen against H. pylori infection. In this study, cholera toxin B subunit (CTB), a mucosal adjuvant, was used to enhance the immunogenicity of a novel Bacillus subtilis spore vaccine expressing CTB-UreB, along with the B. subtilis spore coat protein CotC as a fusion protein. Oral administration of B. subtilis spores expressing CotC-UreB or CotC-CTB-UreB led to increased levels of UreB-specific IgG in serum and UreB-specific IgA in faeces, as well as elevated levels of IL-10 and IFN-γ in splenocytes. In addition, oral administration of CotC-UreB or CotC-CTB-UreB spores induced significant reductions (80.0 and 90.5 %, respectively) in gastric H. pylori bacterial load (1.11±0.36×10 and 0.53±0.21×10 c.f.u., respectively) compared to that of the CotC control group (5.56±1.64×10 c.f.u., P<0.01). Moreover, CotC-CTB-UreB spores were significantly more effective at reducing the bacterial load than CotC-UreB spores (P<0.05). These results indicate that CotC-CTB-UreB-expressing B. subtilis spores are a potential vaccine candidate for the control of H. pylori infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000404
2017-02-20
2019-11-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/1/83.html?itemId=/content/journal/jmm/10.1099/jmm.0.000404&mimeType=html&fmt=ahah

References

  1. Lv X, Song H, Yang J, Li T, Xi T et al. A multi-epitope vaccine CTB-UE relieves Helicobacter pylori-induced gastric inflammatory reaction via up-regulating microRNA-155 to inhibit Th17 response in C57/BL6 mice model. Hum Vaccin Immunother 2014;10:3561–3569 [CrossRef][PubMed]
    [Google Scholar]
  2. Yin SM, Zhang F, Shi DM, Xiang P, Xiao L et al. Effect of posture on (13)C-urea breath test in partial gastrectomy patients. World J Gastroenterol 2015;21:12888–12895 [CrossRef][PubMed]
    [Google Scholar]
  3. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607–615 [CrossRef][PubMed]
    [Google Scholar]
  4. Lee JW, Kim N, Kim JM, Nam RH, Chang H et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206–214 [CrossRef][PubMed]
    [Google Scholar]
  5. Yazbek PB, Trindade AB, Chin CM, dos Santos JL. Challenges to the treatment and new perspectives for the eradication of Helicobacter pylori. Dig Dis Sci 2015;60:2901–2912 [CrossRef][PubMed]
    [Google Scholar]
  6. Anderl F, Gerhard M. Helicobacter pylori vaccination: is there a path to protection?. World J Gastroenterol 2014;20:11939–11949 [CrossRef][PubMed]
    [Google Scholar]
  7. Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2011;8:133–140 [CrossRef][PubMed]
    [Google Scholar]
  8. Yang YC, Kuo TY, Hong ZW, Chang HW, Chen CC et al. High yield purification of Helicobacter pylori neutrophil-activating protein overexpressed in Escherichia coli. BMC Biotechnol 2015;15:23 [CrossRef][PubMed]
    [Google Scholar]
  9. Zhang X, Zhang J, Yang F, Wu W, Sun H et al. Immunization with heat shock protein A and γ-glutamyl transpeptidase induces reduction on the Helicobacter pylori colonization in mice. PLoS One 2015;10:e0130391 [CrossRef][PubMed]
    [Google Scholar]
  10. Bégué RE, Sadowska-Krowicka H. Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol 2010;60:142–146 [CrossRef][PubMed]
    [Google Scholar]
  11. Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol Mol Biol Rev 2000;64:548–572[PubMed][CrossRef]
    [Google Scholar]
  12. Duc H, Hong HA, Atkins HS, Flick-Smith HC, Durrani Z et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 2007;25:346–355 [CrossRef][PubMed]
    [Google Scholar]
  13. Yu J, Chen T, Xie Z, Liang P, Qu H et al. Oral delivery of Bacillus subtilis spore expressing enolase of Clonorchis sinensis in rat model: induce systemic and local mucosal immune responses and has no side effect on liver function. Parasitol Res 2015;114:2499–2505 [CrossRef][PubMed]
    [Google Scholar]
  14. Stasiłojć M, Hinc K, Peszyńska-Sularz G, Obuchowski M, Iwanicki A. Recombinant Bacillus subtilis spores elicit Th1/Th17-polarized immune response in a murine model of Helicobacter pylori vaccination. Mol Biotechnol 2015;57:685–691 [CrossRef][PubMed]
    [Google Scholar]
  15. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO et al. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993;61:4272–4279[PubMed]
    [Google Scholar]
  16. Hashim R, Khatib AM, Enwere G, Park JK, Reyburn R et al. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis 2012;6:e1743 [CrossRef][PubMed]
    [Google Scholar]
  17. Guo L, Liu K, Xu G, Li X, Tu J et al. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbiol Biotechnol 2012;95:1437–1444 [CrossRef][PubMed]
    [Google Scholar]
  18. Zhou Z, Gong S, Li XM, Yang Y, Guan R et al. Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores. J Med Microbiol 2015;64:104–110 [CrossRef][PubMed]
    [Google Scholar]
  19. Wu XC, Lee W, Tran L, Wong SL. Engineering a Bacillus subtilis expression-secretion system with a strain deficient in six extracellular proteases. J Bacteriol 1991;173:4952–4958[PubMed][CrossRef]
    [Google Scholar]
  20. Zhou Z, Xia H, Hu X, Huang Y, Li Y et al. Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis. Vaccine 2008;26:1817–1825 [CrossRef][PubMed]
    [Google Scholar]
  21. Gong YN, Li YM, Yang NM, Li HZ, Guo F et al. Centralized isolation of Helicobacter pylori from multiple centers and transport condition influences. World J Gastroenterol 2015;21:944–952 [CrossRef][PubMed]
    [Google Scholar]
  22. Spizizen J. Transformation of biochemically deficient strains of Bacillus subtilis by deoxyribonucleate. Proc Natl Acad Sci USA 1958;44:1072–1078 [CrossRef][PubMed]
    [Google Scholar]
  23. Zhou ZW, Guan RL, Xia HM, Deng QL, Xie YQ et al. Prokaryotic expression, purification and immunological activity of UreB of Helicobacter pylori isolated from clinical specimens. J Pract Med (Chinese) 2010;26:3673–3675
    [Google Scholar]
  24. Song Y, Liu C, Hui Y, Srivastava K, Zhou Z et al. Maternal allergy increases susceptibility to offspring allergy in association with TH2-biased epigenetic alterations in a mouse model of peanut allergy. J Allergy Clin Immunol 2014;134:1339–1345 [CrossRef][PubMed]
    [Google Scholar]
  25. Mazza P. The use of Bacillus subtilis as an antidiarrhoeal microorganism. Boll Chim Farm 1994;133:3–18[PubMed]
    [Google Scholar]
  26. Tam NK, Uyen NQ, Hong HA, Duc Leh, Hoa TT et al. The intestinal life cycle of Bacillus subtilis and close relatives. J Bacteriol 2006;188:2692–2700 [CrossRef][PubMed]
    [Google Scholar]
  27. Hoa TT, Duc LH, Isticato R, Baccigalupi L, Ricca E et al. Fate and dissemination of Bacillus subtilis spores in a murine model. Appl Environ Microbiol 2001;67:3819–3823[PubMed][CrossRef]
    [Google Scholar]
  28. Uyen NQ, Hong HA, Cutting SM. Enhanced immunisation and expression strategies using bacterial spores as heat-stable vaccine delivery vehicles. Vaccine 2007;25:356–365 [CrossRef][PubMed]
    [Google Scholar]
  29. Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B et al. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 2013;31:2457–2464 [CrossRef][PubMed]
    [Google Scholar]
  30. Baldauf KJ, Royal JM, Hamorsky KT, Matoba N. Cholera toxin B: one subunit with many pharmaceutical applications. Toxins 2015;7:974–996 [CrossRef][PubMed]
    [Google Scholar]
  31. Maconi G, Parente F, Russo A, Vago L, Imbesi V et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?. Am J Gastroenterol 2001;96:359–366 [CrossRef][PubMed]
    [Google Scholar]
  32. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009;70:505–515 [CrossRef][PubMed]
    [Google Scholar]
  33. Tosi MF, Czinn SJ. Opsonic activity of specific human IgG against Helicobacter pylori. J Infect Dis 1990;162:156–162[PubMed][CrossRef]
    [Google Scholar]
  34. Ikewaki J, Nishizono A, Goto T, Fujioka T, Mifune K. Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection. Microbiol Immunol 2000;44:29–39[PubMed][CrossRef]
    [Google Scholar]
  35. Shi T, Liu WZ, Gao F, Shi GY, Xiao SD. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter 2005;10:71–79 [CrossRef][PubMed]
    [Google Scholar]
  36. Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog 2008;44:20–27 [CrossRef][PubMed]
    [Google Scholar]
  37. Huang JM, La Ragione RM, Cooley WA, Todryk S, Cutting SM. Cytoplasmic delivery of antigens, by Bacillus subtilis enhances Th1 responses. Vaccine 2008;26:6043–6052 [CrossRef][PubMed]
    [Google Scholar]
  38. Mauriello EM, Cangiano G, Maurano F, Saggese V, de Felice M et al. Germination-independent induction of cellular immune response by Bacillus subtilis spores displaying the C fragment of the tetanus toxin. Vaccine 2007;25:788–793 [CrossRef][PubMed]
    [Google Scholar]
  39. Nagamine CM, Rogers AB, Fox JG, Schauer DB. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer 2008;122:832–838 [CrossRef][PubMed]
    [Google Scholar]
  40. Shen Z, Feng Y, Rogers AB, Rickman B, Whary MT et al. Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice. Infect Immun 2009;77:2508–2516 [CrossRef][PubMed]
    [Google Scholar]
  41. Liu XF, Hu JL, Quan QZ, Sun ZQ, Wang YJ et al. Systemic immune responses to oral administration of recombinant attenuated Salmonella typhimurium expressing Helicobacter pylori urease in mice. World J Gastroenterol 2005;11:2154–2156[PubMed][CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000404
Loading
/content/journal/jmm/10.1099/jmm.0.000404
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error